Oramed Pharmaceuticals Inc. (ORMP) News

Oramed Pharmaceuticals Inc. (ORMP)

Today's Latest Price: $2.79 USD

0.03 (-1.06%)

Updated Oct 20 4:00pm

Add ORMP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

Filter ORMP News Items

ORMP News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest ORMP News From Around the Web

Below are the latest news stories about Oramed Pharmaceuticals Inc that investors may wish to consider to help them evaluate ORMP as an investment opportunity.

Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients

NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for Oramed by a third party research firm. The survey included qualitative interviews with healthcare providers as well as type 1 (T1D) and type 2 (T2D) diabetes patients regarding Oramed's lead oral insulin product, ORMD-0801, which is headed into a Phase III trial. Forty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed. There was strong support among these health care providers for ...

Benzinga | September 15, 2020

Company News for Jul 16, 2020

Companies in the new are: INFY, PGR, BE, ORMP

Yahoo | July 16, 2020

Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin

NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801). Based on the FDA's feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application (BLA) that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. Oramed's Chief Executive Nadav Kidr...

Benzinga Feeds | July 15, 2020

Oramed Pharmaceuticals EPS beats by $0.10, beats on revenue

Oramed Pharmaceuticals (ORMP): Q3 GAAP EPS of -$0.10 beats by $0.10.Revenue of $0.68M (flat Y/Y) beats by $0.17M.Press Release...

Seeking Alpha | July 8, 2020

Insulin in Pill Form Would Be a Bonanza for Oramed

Drug trials suggest first commercial oral insulin capsule may be on the horizon Continue reading...

Yahoo | July 8, 2020

ORMP: Positive Takeaways of Preliminary NASH Study Findings

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), a clinical-stage pharmaceutical company with a proprietary oral protein delivery platform technology, presented preliminary data findings from its NASH study at the American Diabetes Association Scientific Session 2020 this week. The company announced that its NASH study has shown ORMD-0801 to be

Yahoo | June 19, 2020

Oramed Announces Positive Initial Clinical Trial Results for Treatment of NASH With Oral Insulin

NEW YORK, June 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that its pilot study of its oral insulin candidate ORMD-0801…

PR Newswire | June 15, 2020

Newsflash: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Analysts Have Been Trimming Their Revenue Forecasts

Today is shaping up negative for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shareholders, with the analysts delivering...

Yahoo | June 9, 2020

Oramed Pharmaceuticals Inc. (ORMP): Are Hedge Funds Right About This Stock?

In this article we will take a look at whether hedge funds think Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips […]

Yahoo | June 4, 2020

Oramed Pharmaceuticals to Present at the 80th American Diabetes Association Scientific Session, to be Held Virtually This Year in June

NEW YORK, May 5, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present during the 80th American Diabetes Association…

PR Newswire | May 5, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5724 seconds.